As more agents become approved, it’s important to individualize therapy for this patient population, Sara A. Hurvitz, MD, said at the 37th Annual Miami Breast Cancer Conference.
The study found that 31 to 60 days seems to be the ideal time period to begin adjuvant chemotherapy in HER2-positive breast cancer patients.
This study sought to determine the patient and tumor characteristics associated with positive lymph nodes status in T1 HER2-positive breast cancer.
HSD3B1 may help identify more men who are likely to benefit from escalated androgen receptor axis inhibition beyond gonadal testosterone suppression according to the researchers.
The use of statins, alone or in combination with metformin, was found to be associated with lower all-cause and prostate cancer mortality among high-risk patients, particularly in post-diagnostic settings.
These findings highlight the need to raise public awareness of the importance of self-skin examination, and to encourage clinicians to have a lower threshold for undertaking skin examinations in bereaved individuals, according to the researchers.
Madan Jagasia, MBBS, MS, of the Vanderbilt University Medical Center discussed the next steps in treating acute graft versus host disease with ruxolitinib.
In a paper published in The BMJ, the authors provide a summary for the diagnosis, treatment, and monitoring of thyroid nodules.
Phase II trial results found that phenelzine, a monoamine oxidase inhibitor typically used as an antidepressant, showed promise for patients with biochemical recurrent castrate-sensitive prostate cancer.
A study published in Cancer suggests meeting the ACS guidelines for physical activity correlates with improved health-related quality of life and lower depression levels.
Mark Schroeder, MD, detailed 3 different potential treatments for acute graft versus host disease.
Dylan Essner discussed the implementation of documentation tools and CRS, ICANS and ICE flow sheets within CAR T-cell therapy.
Kura Oncology’s leading drug candidate, tipifarnib, was granted fast track designation by the FDA to treat adults of T-cell lymphomas.
The new guidelines provide additional guidance for healthcare providers to better recognize and diagnose breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
A study, published in Nature Cancer, demonstrates the quick and evolving revolutions of resistance mechanisms in small cell lung cancer.